checkAd

    ASTR - "Psoriasis": Hilfe für 180 Mio. Menschen - 500 Beiträge pro Seite

    eröffnet am 01.02.02 14:56:12 von
    neuester Beitrag 15.03.02 16:50:19 von
    Beiträge: 10
    ID: 544.328
    Aufrufe heute: 0
    Gesamt: 263
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 01.02.02 14:56:12
      Beitrag Nr. 1 ()
      ASTR

      1. ASTRALIS ist ein Biotech-Unternehmen das ein Medikament "Psoraxine" gegen Psoriasis (Schuppenflechte) entwickelt hat

      2. Unter dieser Krankheit leiden weltweit ca. 180 Mio. Menschen, der Markt wird auf 2 Mrd. $ geschätzt.

      3. Es gibt bislang kein wirksames Heilmittel.

      4. Am 12. Dezember hat ASTRALIS mit SKYEPHARMA eine Vereinbarung über die Entwicklung und den Vertrieb von "Psoraxine" getroffen.


      SkyePharma and Astralis Enter Agreements For Promising New Psoriasis Treatment
      /FROM PR NEWSWIRE NEW YORK 800-776-8090/ [STK] SKYE ASTR [IN] MTC [SU] FNC LIC TO BUSINESS AND MEDICAL EDITORS:

      SkyePharma and Astralis Enter Agreements
      For Promising New Psoriasis Treatment

      LONDON, and FLORHAM PARK, N.J., Dec. 12 /PRNewswire -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) and Astralis LTD (OTC Bulletin Board: ASTR) announce several agreements concerning the formulation and development of Astralis` novel injectable vaccine therapy, Psoraxine(TM), for the treatment of all forms of psoriasis, a chronic skin disorder that affects approximately 3% of the world population.

      Under the terms of a technology access agreement, SkyePharma will receive from Astralis a US$5 million license fee, which will be recognised as revenue over the lifetime of the contract, for access to DepoFoam and other relevant drug delivery technologies. In addition, through a service agreement, SkyePharma will provide all development, manufacturing, pre-clinical and clinical development services for second generation Psoraxine, up to the completion of Phase II clinical studies. On completion of Phase II studies, Astralis will offer SkyePharma the option to acquire the worldwide licensing and distribution rights to Psoraxine. If SkyePharma does not take the option, Astralis will seek a marketing partner to fund Phase III clinical studies and to provide a sales and marketing infrastructure. It is anticipated that an Investigational New Drug (IND) application to start Phase I-B clinical studies will be filed with the US Food and Drug Administration in the first half of 2002.

      In a separate transaction, SkyePharma will make a total equity investment in Astralis of up to US$20 million in convertible preferred shares, on payment for which SkyePharma will own 15.3% of Astralis. SkyePharma will make an initial investment of US$10 million on signature of the agreement. The remaining US$10 million investment will be paid at times and in quantities, amongst other conditions, dependent on the date of filing the US IND, up to January 31, 2003.

      There is no approved cure for psoriasis. Most approved treatment protocols provide temporary or incomplete relief and may, with certain systemic treatments, cause serious side effects. Psoraxine, developed by Astralis` Chairman Dr. Jose Antonio O`Daly MD, PhD, is a protein that stimulates cells from the patient`s immune system to reverse the inflammatory process responsible for psoriasis symptoms.

      Astralis has completed clinical studies in Venezuela using first generation Psoraxine to treat 3,000 psoriasis patients, the majority of whom responded positively with few side effects. Of the 3,000 treated patients, 638 achieved complete remission, whilst nearly half of all patients experienced a reduction in disease of between 70% and 90%, as measured by the Psoriasis Area and Severity Index (PASI), a validated outcomes measure. Overall, 96% of the patients had a positive response to Psoraxine, although these results have not yet been independently verified.

      Professor James Leyden, a Board member of the American Academy of Dermatology and past chairman of the Dermatology Foundation, said, "I have had the opportunity to review the data generated in Venezuela, and was very encouraged by the results. I believe Psoraxine could be an exciting new treatment alternative for many of the world`s psoriasis sufferers. We look forward to becoming an integral part of the ongoing clinical program."

      Michael Ashton, SkyePharma`s chief executive officer commented, "Our ability to provide Astralis with manufacturing, pre-clinical, clinical and regulatory services, as well as access to a broad drug delivery technology platform, makes SkyePharma ideally suited to their needs. We, in turn, are very excited by the opportunity to share in Astralis` promising discovery. It is rare to find a potential drug that has already shown such encouraging, early-stage clinical results in around 3,000 patients."

      Astralis` Chief Executive Officer, Mike Ajnsztajn, said, "We are excited to enter into this agreement with SkyePharma, because they have a proven track record in achieving FDA approval for novel products as evidenced by the dermatological product, Solaraze, indicated for actinic keratosis. This relationship will enable us to validate the results from our prior clinical studies and to move aggressively toward gathering the necessary data for US regulatory and marketing approval. SkyePharma`s equity investment confirms our collective commitment to introduce this promising product."

      This press release may contain forward-looking statements regarding SkyePharma PLC or Astralis LTD. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that Psoraxine will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. SkyePharma PLC and Astralis LTD undertake no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

      Notes

      Astralis LTD, an emerging biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine, the company`s first product, is an innovative drug under development for psoriasis, and is based on the company`s discovery of a new gene sequence of proteins. To date, clinical data suggest remission of this skin condition in patient trials in Venezuela.

      SkyePharma PLC, an established drug delivery company, based in the UK, provides innovative services to major pharmaceutical partners from the point of drug discovery through the approval process. Its five technologies, oral, injectable, inhalation, topical, and nanoparticulate solubilisation encompass the vast majority of delivery systems in use by the pharmaceutical industry. For more information, visit SkyePharma`s web site at http://www.skyepharma.com . Psoriasis

      Psoriasis is a chronic, genetically based remitting and relapsing scaly and inflammatory skin disorder that affects approximately 3% of the world`s population. Psoriasis symptoms result from the overproduction of skin by blood cells associated with the immune system. These blood cells become confused and act as though the skin was damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. The overproduction of skin can cause everything from itchy rash like patches to painful pustules and massive inflammation. Most current treatments are sub-optimal and some systemic treatments can cause serious side effects.

      Additional information can be obtained from:
      International Federation of Psoriasis Associations at
      http://www.ifpa-pso.org
      US National Psoriasis Foundation at http://www.psoriasis.org
      The Psoriasis Association (UK) Tel: +44 (0) 1604 711129

      MAKE YOUR OPINION COUNT - Click Here
      http://tbutton.prnewswire.com/prn/11690X28677374


      5. Gestern kam die Bestätigung über die Finanzierung von SKYEPHARMA und den Mittelfluß für 2002.



      ASTRALIS LTD, (SC 13D/A) Statement of Ownership Filed By SKYEPHARMA PLC

      --------------------------------------------------------------------------------

      Page 1 of 6

      UNITED STATES
      SECURITIES AND EXCHANGE COMMISSION
      Washington, D.C. 20549

      SCHEDULE 13D

      Under the Securities Exchange Act of 1934
      (Amendment No. 1)*

      nications)

      January 31, 2002
      --------------------------------------------------------------------------------
      (Date of Event which Requires Filing of this Statement)



      --------------------------------------------------------------------------------

      1 In order to facilitate the consummation of the transaction contemplated by the Purchase Agreement by and between Astralis Ltd. and SkyePharma PLC, dated as of December 10, 2001 (the ?Purchase Agreement?), Astralis Ltd. and SkyePharma PLC entered into a Stockholders Agreement between SkyePharma PLC, Astralis Ltd. and the other parties listed therein, dated as of December 10, 2001 (the ?Stockholders Agreement?), whereby each stockholder agreed to vote its shares of Common Stock and take all other actions necessary to elect the independent directors nominated by the Board of Directors (the ?Board?) and to elect the nominee nominated to the Board by SkyePharma. SkyePharma does not have the right to dispose (or direct the disposition of) any of the 24,800,000 shares of Common Stock owned by the other parties to the Stockholders Agreement. Accordingly, SkyePharma expressly disclaims beneficial ownership of all such shares.

      2 SkyePharma is currently the beneficial owner of 200,000 shares of Common Stock and 1,250,000 shares of Series A Convertible Preferred Stock, and may acquire another 750,000 shares of Series A Convertible Preferred Stock pursuant to the Purchase Agreement. Accordingly, SkyePharma has beneficial ownership of 8,200,000 shares of Common Stock, assuming the purchase of the 750,000 additional shares of Series A Convertible Preferred Stock and the conversion of all shares of Series A Convertible Preferred Stock owned or to be purchased by SkyePharma into Common Stock at the current conversion rate of four to one.

      3 Based on 37,576,179 shares of Common Stock outstanding on January 31, 2002 and the conversion of 2,000,000 shares of Series A Convertible Preferred Stock into 8,000,000 shares of Common Stock.


      --------------------------------------------------------------------------------

      SkyePharma PLC, a company incorporated under the laws of England and Wales (?SkyePharma?), hereby amends and supplements the statement on 13D previously filed by it, with respect to the Common Stock, par value $0.0001 per share (the ?Common Stock?), of Astralis Ltd., a Delaware corporation (the ?Issuer?), which is issuable upon conversion of the Series A Convertible Preferred Stock, par value $0.001 per share (the ?Convertible Preferred Stock?) held by SkyePharma .

      Item 3. Source and Amount of Funds or Other Consideration.

      The source of funds for the two million shares of Convertible Preferred Stock convertible into eight million shares of Common Stock to which this Statement relates was and will be SkyePharma?s working capital. The total amount was 20,000,000 U.S. dollars in cash of which 10,000,000 U.S. dollars was paid on December 10, 2001, 2,500,000 U.S. dollars was paid on January 31, 2002, and the remaining 7,500,000 U.S. dollars will be paid in three equal instalments on April 30, 2002, July 31, 2002, and January 31, 2003, in each case in accordance with the Purchase Agreement by and between the Issuer and SkyePharma, dated as of December 10, 2001 (the ?Purchase Agreement?).



      Page 4 of 6

      Item 4. Purpose of Transaction.

      The purpose of the acquisition of the Convertible Preferred Stock by SkyePharma was and is for investment.

      Pursuant to the terms of the Purchase Agreement, on January 31, 2002 SkyePharma purchased 250,000 newly-issued shares of Convertible Preferred Stock convertible into 1,000,000 shares of Common Stock. On each of April 30, 2002, July 31, 2002, and January 31, 2003, SkyePharma will purchase an additional 250,000 newly-issued shares of Convertible Preferred Stock convertible into 1,000,000 shares of Common Stock, for a total of 750,000 shares of Convertible Preferred Stock convertible into 3,000,000 shares of Common Stock, subject to the conditions set forth in sections 5, 6 and 7 of the Purchase Agreement.

      Item 5. Interest in Securities of the Issuer.

      The percentage interest held by SkyePharma presented below is based on the number of shares of Common Stock reported by the Issuer to SkyePharma as outstanding at January 31, 2002. Assuming (i) the purchase of an additional 750,000 shares of Convertible Preferred Stock under the Purchase Agreement and (ii) the conversion of all shares of Convertible Preferred Stock owned and to be acquired by SkyePharma into Common Stock, SkyePharma would be the beneficial owner of 8,200,000 shares of the Common Stock, representing approximately 18.0% of the Common Stock issued and outstanding. Based on information reported by the Issuer to SkyePharma, Jose Antonio O?Daly (?Mr. O?Daly?) is the beneficial owner of 13,640,000 shares of the Common Stock representing approximately 36.3% of the Common Stock issued and outstanding, Mike Ajnsztajn (?Mr. Ajnsztajn?) is the beneficial owner of 8,680,000 shares of the Common Stock representing approximately 23.1% of the Common Stock issued and outstanding and Gaston Liebhaber (?Mr. Liebhaber?) is the beneficial owners of 2,480,000 shares of the Common Stock representing approximately 6.6% of the Common Stock issued and outstanding.

      Based on information reported by the Issuer to SkyePharma, on January 10, 2002 Messrs. O?Daly, Ajnsztajn and Liebhaber transferred respectively 275,000, 175,000 and 50,000 shares of Common Stock to Mr. Manolo Tarabay for consulting services rendered in connection with their efforts to raise capital for the Issuer.

      Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
      to Securities of the Issuer.

      SkyePharma and the Issuer entered into the Purchase Agreement pursuant to which SkyePharma shall purchase 750,000 newly-issued shares of Convertible Preferred Stock convertible into 3,000,000 shares of Common Stock,



      Page 5 of 6

      on or before January 31, 2003, subject to the conditions set forth in sections 5, 6 and 7 of the Purchase Agreement.

      Item 7. Material to be filed as Exhibits.

      1. Purchase Agreement, dated as of December 10, 2001, among the Issuer, incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K of the Issuer, filed by the Issuer on December 14, 2001 (File Number 000-30997).

      2. Stockholders Agreement, dated as of December 10, 2001, among the Issuer, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K of the Issuer, filed by the Issuer on December 14, 2001 (File Number 000-30997).

      FAZIT: Für mich ist der stock einen trade wert.

      GN
      Avatar
      schrieb am 02.02.02 00:59:50
      Beitrag Nr. 2 ()
      Guenter...

      Den Daumen immer am Puls der Zeit!

      Schaut wenn ich es so überfliege nicht schlecht aus!

      Gruß

      morchel
      Avatar
      schrieb am 04.02.02 15:21:45
      Beitrag Nr. 3 ()
      Heute gibts ja schöne news von Astralis...fdas hereinstellen überlasse ich dem Trainer....;)

      gibts auch ne homepage von Astralis?

      morchel
      Avatar
      schrieb am 04.02.02 15:35:01
      Beitrag Nr. 4 ()
      @morchel

      Danke Dir morchel, in der Tat, die Sache zwischen ASTR und SKYE scheint grundsolide zu sein und die Finanzierung für "Psoraxine" ist gesichert:

      February 04, 2002 08:01

      Astralis Receives $2.5 Million Payment From SkyePharma Pursuant to Original Agreement
      Jump to first matched term

      FLORHAM PARK, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Astralis LTD (OTC Bulletin Board: ASTR ) announced today that it received a $2.5 million payment from SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) under the December 2001 Stock Purchase Agreement. The $2.5 million represents the first installment of the total $10 million, due from SkyePharma, the remaining installments of which are scheduled for payment through January 31, 2003.

      Under the terms of the original equity agreement, SkyePharma will make a total equity investment in Astralis of up to $20 million in convertible preferred shares, following which SkyePharma will own 15.3% of Astralis. SkyePharma has already made an initial investment of $10 million on December 10, 2001, the effective date of the agreement.

      In addition to the original equity investment, SkyePharma and Astralis signed a technology agreement that provides Astralis with access to SkyePharma`s DepoFoam and other relevant drug delivery technologies, as well as a service agreement, whereby SkyePharma will provide all development, pre-clinical and clinical development services for PSORAXINE(TM), Astralis` novel injectable vaccine therapy for the treatment of all forms of Psoriasis up to the completion of Phase II clinical studies.

      "SkyePharma`s investment in Astralis represents a further commitment by both companies toward developing a novel product for the treatment of Psoriasis and other innovative pharmaceutical entities targeting immunodeficient disorders and skin diseases," commented Mike Ajnsztajn, Astralis` president and chief executive officer. "This preferred equity investment provides additional capital to Astralis for the scheduled transfer of our proprietary technology from Venezuela to the U.S. as well as for the preliminary procedures required for filing an IND application for PSORAXINE."

      Astralis Ltd. is an emerging biotechnology company focusing on the research and development of novel treatments for immune system disorders and skin diseases. PSORAXINE, the company`s first product, is an innovative drug under development for all forms of psoriasis. Astralis has completed clinical studies in Venezuela using PSORAXINE to treat nearly 3,000 Psoriasis patients, the majority of whom responded positively with few side effects. Of the nearly 3,000 treated patients, 638 achieved complete remission, while nearly half of all patients experienced a reduction in disease of between 70% and 90%, as measured by the Psoriasis Area and Severity Index (PASI), a validated outcomes measure. Overall, 96% of the patients had a positive response to PSORAXINE, although these results have not yet been independently verified.

      There is no approved cure for Psoriasis. Most approved treatment protocols provide temporary or incomplete relief and may, with certain systemic treatments, cause serious side effects. PSORAXINE, developed by Astralis` Chairman Dr. Jose Antonio O`Daly M.D., Ph.D., is a protein-based therapy that stimulates cells from the patient`s immune system to reverse the inflammatory process responsible for psoriasis symptoms.

      This press release may contain forward-looking statements regarding Astralis LTD. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that PSORAXINE will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Astralis LTD undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

      Notes to the Editor

      Astralis LTD, an emerging biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and skin diseases. Psoraxine, the company`s first product, is an innovative drug under development for psoriasis, and is based on the company`s discovery of a new gene sequence of proteins. To date, clinical data suggest remission of this skin condition in patient trials in Venezuela.

      SkyePharma PLC, one of the world`s leading drug delivery companies, provides innovative services to major pharmaceutical partners from the point of drug discovery through the approval process. Its five technologies, oral, injectable, inhalation, topical, and nanoparticulate solubilisation encompass the vast majority of delivery systems in use by the pharmaceutical industry. For more information, visit SkyePharma`s web site at http://www.skyepharma.com.

      Psoriasis

      Psoriasis is a chronic, genetically based remitting and relapsing scaly and inflammatory skin disorder that affects approximately 3% of the world`s population. Psoriasis symptoms result from the overproduction of skin by blood cells associated with the immune system. These blood cells become confused and act as though the skin was damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. The overproduction of skin can cause everything from itchy rash like patches to painful pustules and massive inflammation. Most current treatments are sub-optimal and some systemic treatments can cause serious side effects.

      Additional information can be obtained from:
      International Federation of Psoriasis Associations at www.ifpa-pso.org
      US National Psoriasis Foundation at www.psoriasis.org
      The Psoriasis Association (UK) Tel: +44 (0) 1604 711129

      MAKE YOUR OPINION COUNT - Click Here
      http://tbutton.prnewswire.com/prn/11690X56286083

      SOURCE Astralis LTD

      /CONTACT: Mike Ajnsztajn, Chief Executive Officer, or Gina Tedesco,
      Chief Financial Officer, both of Astralis LTD, +1-973-377-8838,
      info@astralisltd.com; or David Perry of In-Site Communications,
      +1-212-759-5665, dperry@insitecony.com, for Astralis LTD/

      /Web site: http://www.skyepharma.com/

      Soweit ich weiß, gibt es keine Web-Seite von ASTR. Finde ich auch nicht schlimm, das sind reine Forscher und Entwickler und die Produktion und den Vertrieb überlassen sie Leuten, die es besser können: SKYEPHARMA. Die haben eine Web-Seite...

      GN
      Avatar
      schrieb am 04.02.02 15:59:21
      Beitrag Nr. 5 ()
      selbstverständlich gibt es ne domain!

      Sie ist nur noch nicht bebaut1

      http://www.astralisltd.com/


      Sie wurde aber erst am 17 Dezember 2001 registriert!


      morchel

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 04.02.02 16:05:04
      Beitrag Nr. 6 ()
      @morchel

      Würde mich mal interessieren, wann bei ASTRALIS/SKYEPHARMA mit der Marktreife von "Proraxine" gerechnet wird. Meine Recherche bei SKYE ergab zumindest, daß die Testreihen aus Venezuela in der zweiten Hälfte 2002 bestätigt werden sollen und dann die Zulassungen laufen...

      GN
      Avatar
      schrieb am 07.03.02 19:50:37
      Beitrag Nr. 7 ()
      ASTR

      Bei Astralis scheint sich was anzubahnen...

      ASTRALIS LTD (U) 2,05 +0,37 +22,02%

      WKN: - Börse: Nasdaq OTC Symbol: ASTR.NAP 07.03. 19:08

      ;)

      GN
      Avatar
      schrieb am 08.03.02 16:11:51
      Beitrag Nr. 8 ()
      ASTR



      ;)

      GN
      Avatar
      schrieb am 15.03.02 04:41:43
      Beitrag Nr. 9 ()
      Thursday March 14, 4:49 pm Eastern Time

      Press Release

      SOURCE: Astralis Ltd

      Astralis Ltd Reports 2001 Results

      FLORHAM PARK, N.J.--(BUSINESS WIRE)--March 14, 2002--Astralis Ltd (OTCBB:ASTR - news) announced today its results for the initial period ending
      December 31st, 2001.

      For the period from March 12, 2001, which was the date of inception though December 31, 2001, the Company recorded a net loss of $ 6.2 million, or $0.23 per share.
      The Company, which is in the developing stage, had no revenue during this period. Total shareholders` equity as of December 31, 2001, was $9.1 million and the
      Company had cash balances totalling $4.5 million as of December 31, 2001.

      Research and development expenses amounted to $3.2 million. This reflected spending on continued research for Psoraxine(TM), Astralis` first drug candidate for
      treatment of Psoriasis which began in early 2001, as well as payments to SkyePharma for regulatory and development services pursuant to a service agreement signed
      in December 2001. The Company anticipates that R&D expenses will increase in 2002, as Astralis and SkyePharma continue efforts relating to development of
      Psoraxine(TM) for psoriasis. It is anticipated that an Investigational New Drug (IND) application to start clinical studies will be filed with the US Food and Drug
      Administration in the second half of 2002.

      Astralis Ltd. is an emerging biotechnology company focusing on the research and development of novel treatments for immune system disorders and skin diseases.
      PSORAXINE(TM), the company`s first product candidate, is under development for the treatment of all forms of psoriasis. Astralis has completed clinical studies in
      Venezuela using PSORAXINE(TM) to treat nearly 3,000 Psoriasis patients, the majority of whom responded positively with few side effects.

      Of the nearly 3,000 treated patients, 648 achieved complete remission, while nearly half of all patients experienced a reduction in disease of between 70% and 99%, as
      measured by the Psoriasis Area and Severity Index (PASI), a validated outcomes measure. Overall, 96% of the patients had a positive response to PSORAXINE(TM),
      although these results have not yet been independently verified.

      There is no approved cure for Psoriasis. Most approved treatment protocols provide temporary or incomplete relief and may, with certain systemic treatments, cause
      serious side effects. PSORAXINE(TM) the company`s first product candidate, developed by Astralis` Chairman Dr. Jose Antonio O`Daly M.D., Ph.D., is intended to be
      a protein-based therapy that stimulates cells from the patient`s immune system to reverse the inflammatory process responsible for psoriasis symptoms.

      This press release contains forward-looking statements regarding Astralis Ltd. There can be no assurance that PSORAXINE(TM) will be successfully developed or
      manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be
      received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Astralis Ltd undertakes no obligation to revise or update
      any such forward-looking statement to reflect events or circumstances after the date of this release.

      Astralis Ltd
      (A Development Stage Entity)
      Selected Statement of Operation Information
      March 12, 2001 (Date of Inception) to December 31, 2001


      Revenues --

      Total Operating Expenses 4,084,619

      Loss from Operations 4,084,619

      Other Income

      Interest Income (9,255)

      Net Loss (4,075,364)

      Preferred Stock Dividend (2,120,000)

      Net Loss to Common Stockholder (6,195,364)

      Pro Forma Information (Unaudited)

      Net Loss (6,195,364)

      Pro forma tax provision --

      Pro forma net loss (6,195,364)

      Basic and diluted loss per common share (0.23)


      Notes to the Editor

      Astralis Ltd, an emerging biotechnology company based in New Jersey, focuses on the research and development of novel treatments for immune system disorders and
      skin diseases. Psoraxine(TM), the company`s first product candidate, is under development for the treatment of psoriasis, and is based on the discovery by the
      Company`s founder of a new gene sequence of proteins. To date, clinical data suggest remission of this skin condition in patient trials in Venezuela. For more
      information, visit Astralis` web site at http://www.astralisltd.com

      SkyePharma PLC, one of the world`s leading drug delivery companies, provides innovative services to major pharmaceutical partners from the point of drug discovery
      through the approval process. Its five technologies, oral, injectable, inhalation, topical, and nanoparticulate solubilisation encompass the vast majority of delivery systems
      in use by the pharmaceutical industry. For more information, visit SkyePharma`s web site at http://www.skyepharma.com

      Psoriasis

      Psoriasis is a chronic, genetically based remitting and relapsing scaly and inflammatory skin disorder that affects approximately 3% of the world`s population. Psoriasis
      symptoms result from the overproduction of skin by blood cells associated with the immune system. These blood cells become confused and act as though the skin was
      damaged, manufacturing skin cells at a much faster rate than is required by undamaged skin. The overproduction of skin can cause everything from itchy rash like
      patches to painful pustules and massive inflammation. Most current treatments are sub-optimal and some systemic treatments can cause serious side effects.

      Additional information can be obtained from: International Federation of Psoriasis Associations at www.ifpa-pso.org US National Psoriasis Foundation at
      www.psoriasis.org The Psoriasis Association (UK) Tel: +44 (0) 1604 711129
      Avatar
      schrieb am 15.03.02 16:50:19
      Beitrag Nr. 10 ()
      ASTR

      Die Zahlen scheinen die Anleger nicht verschreckt zu haben. Ist allerdings auch kein Wunder, weil sich ASTR mit einem riesigen Konzern als Investor zusammengetan hat. Die Finanzen sind damit gesichert. Spannend wird die Phase der Zulassung für das Medikament...

      GN


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      ASTR - "Psoriasis": Hilfe für 180 Mio. Menschen